Unlocking the Potential of Ethosomes in Dermatological Treatments

In recent times, Ethosome has become a new promising pharmaceutical nano-carrier for the development of innovative dermal and transdermal therapies that help in the treatment of various skin diseases like skin allergies, urticaria, melisma, eczema, melanoma, and other skin disease. Ethosome is a non-invasive, modified phospholipid-based elastic, soft vesicular nano-carrier with high ethanol content. Ethanol in this formulation facilitates rapid penetration of the drug into the skin accelerating cell membrane lipid fluidity. After permeation into the skin, those get fused with the cell membrane lipids and release the loaded drug. BCS III & IV drugs, having low permeability, can be developed with ethosomal systems. Histamine is one of the responsible biogenic factors for itching, skin wheals, allergies, other skin disorders, etc., so incorporation of low permeable antihistaminic drugs in ethosome is an emerging prospect in the field of dermatology and cosmetology. Ethosomes reflect positive insights to overcome side effects associated with conventional oral therapy, quick onset of action, and targeted drug delivery to inflamed skin. The concept of ethosome is considered advantageous over liposome to be more penetrable to the skin. Besides the need for further pharmacokinetic and pharmacodynamics studies on ethosome, it seems to significantly hold a great contemplation for the delivery of medicaments in the skin through different pathways.